HomeCompareAPLT vs PLD

APLT vs PLD: Dividend Comparison 2026

APLT yields 1941.75% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLT wins by $7549549074.83M in total portfolio value
10 years
APLT
APLT
● Live price
1941.75%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7549549081.34M
Annual income
$6,855,073,294,458,854.00
Full APLT calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — APLT vs PLD

📍 APLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLTPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLT + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APLT pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLT
Annual income on $10K today (after 15% tax)
$165,048.54/yr
After 10yr DRIP, annual income (after tax)
$5,826,812,300,290,026.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, APLT beats the other by $5,826,812,295,822,055.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLT + PLD for your $10,000?

APLT: 50%PLD: 50%
100% PLD50/50100% APLT
Portfolio after 10yr
$3774774543.92M
Annual income
$3,427,536,649,857,645.00/yr
Blended yield
90.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

APLT
Analyst Ratings
5
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$0.25
+142.7% upside vs current
Range: $0.25 — $0.25
Altman Z
-35.3
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLT buys
0
PLD buys
0
No recent congressional trades found for APLT or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLTPLD
Forward yield1941.75%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$7549549081.34M$6.50M
Annual income after 10y$6,855,073,294,458,854.00$5,256,436.18
Total dividends collected$7500143229.39M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$0.25$136.00

Year-by-year: APLT vs PLD ($10,000, DRIP)

YearAPLT PortfolioAPLT Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$204,875$194,174.76$11,255$555.24+$193.6KAPLT
2$3,937,114$3,717,897.78$13,062$1,018.59+$3.92MAPLT
3$70,986,064$66,773,352.36$15,903$1,926.67+$70.97MAPLT
4$1,201,115,737$1,125,160,648.71$20,839$3,823.32+$1201.09MAPLT
5$19,077,920,928$17,792,727,089.23$30,464$8,166.08+$19077.89MAPLT
6$284,535,588,112$264,122,212,719.20$52,054$19,457.30+$284535.54MAPLT
7$3,985,969,128,556$3,681,516,049,275.53$109,886$54,188.93+$3985969.02MAPLT
8$52,464,234,462,079$48,199,247,494,524.41$304,030$186,451.18+$52464234.16MAPLT
9$649,042,791,475,683$592,906,060,601,258.60$1,166,125$840,813.32+$649042790.31MAPLT
10$7,549,549,081,337,835$6,855,073,294,458,854.00$6,504,190$5,256,436.18+$7549549074.83MAPLT

APLT vs PLD: Complete Analysis 2026

APLTStock

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Full APLT Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this APLT vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLT vs SCHDAPLT vs JEPIAPLT vs OAPLT vs KOAPLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.